Belgium· BE-AMP-SAM662030-00
Ebglyss 250 mg
A lebrikizumab product containing lebrikizumab, registered in Belgium by Almirall. The same ATC class is registered in 15 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Lebrikizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC D11AH10 (lebrikizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Lebrikizumab · ATC D11AH10
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lebrikizumab costs, country by country.
Normalised to the WHO defined daily dose (8.9 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lebrikizumab · price per daily dose (8.9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$20.32
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Lebrikizumab
- Manufacturer
- Almirall
- Country
- Belgium (BE)
- ATC code
- D11AH10
- ATC class
- Lebrikizumab
- Defined daily dose
- 8.9 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 3
2 priced- be_apb4785507EUR 3011.01
- be_apb4785499EUR 2011
- be_apb7742315
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lebrikizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaEBGLYSSAlmirall, S.A., Barcelona
- NorwayEbglyssAlmirall, S.A.
- IcelandEbglyssAlmirall S.A.*
- SpainEBGLYSS 250 MG SOLUCION INYECTABLE EN JERINGA PRECARGADAAlmirall S.A.
- SwedenEbglyss 250 mg Injektionsvätska, lösning i förfylld injektionspennaAlmirall S.A.
- PolandEbglyssAlmirall, S.A.
- United StatesEBGLYSSEli Lilly and Company
- SwitzerlandEbglyss
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ebglyss
- Liechtenstein · Ebglyss
- Norway · Ebglyss
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dbe6e7be-55aa-4709-b307-55f7b035d027 GET /v1/drugs/dbe6e7be-55aa-4709-b307-55f7b035d027?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Ebglyss 250 mg",
"name_fr": "Ebglyss 250 mg",
"name_nl": "Ebglyss 250 mg",
"amp_code": "SAM662030-00",
"strengths": [
"250.0000",
"250.0000"
],
"pack_count": 6,
"substances": [
"Lebrikizumab",
"Sucrose",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Lebrikizumab",
"authorisation_numbers": [
"EU/1/23/1765/009",
"EU/1/23/1765/010",
"EU/1/23/1765/012",
"EU/1/23/1765/008",
"EU/1/23/1765/011",
"EU/1/23/1765/007"
]
}See everything about lebrikizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.